Galectin Therapeutics Inc GALT
$3.68 $0.11 (3.08%) 1D
Last Updated: Aug 21, 12:00 AM·NASDAQ
Pricing for US stocks is delayed by 24 hours
GALT Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Galectin Therapeutics Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Galectin Therapeutics Inc. Stock Analysis GALT
United States Health Care Small Cap Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. The company is headquartered in Norcross, Georgia and currently employs 9 full-time employees. The company went IPO on 2002-09-04. The Company’s drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company’s lead drug, belapectin, is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. The firm's additional development programs are in the treatment of combination immunotherapy for advanced head and neck cancers and other malignancies.
Galectin Therapeutics Inc (GALT) Chart
Financial Metrics & Statements of Galectin Therapeutics Inc (GALT)
FAQ's for Galectin Therapeutics Inc (GALT)
- As of August 2026, Galectin Therapeutics Inc GALT is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Galectin Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Galectin Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Galectin Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Galectin Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Galectin Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Galectin Therapeutics Inc (GALT)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
